INVESTIGATION OF THE EARLY KILLING OF STAPHYLOCOCCUS-AUREUS BY DAPTOMYCIN BY USING AN INVITRO PHARMACODYNAMIC MODEL

被引:17
作者
VANCEBRYAN, K
LARSON, TA
ROTSCHAFER, JC
TOSCANO, JP
机构
[1] VET AFFAIRS MED CTR,MINNEAPOLIS,MN 55417
[2] ST PAUL RAMSEY MED CTR,ST PAUL,MN 55101
关键词
D O I
10.1128/AAC.36.10.2334
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The purpose of this study was to develop a pharmacodynamic model to describe the dependency of the rate of Staphylococcus aureus killing upon the concentration of daptomycin. A range of free (unbound) daptomycin concentrations ranging from 0.12 to 27 times the MIC were simulated in the peripheral compartment of a two-compartment pharmacokinetic model. Log-linear regression of free daptomycin concentrations versus growth or kill rate constants showed a significant correlation (r = -0.90; P < 0.0001). A Lineweaver-Burk plot of the reciprocal transformation of these data yielded a poor fit (r = -0.38; P > 0.05). When a Lineweaver-Burk-type regression analysis was performed on the reciprocal of the change in the rate constant rather than the rate constant itself, the result demonstrated good correlation (r = 0.90; P < 0.0001). The observations were also well described by a sigmoidal maximum plateau pharmacologic effect model, in which the pharmacologic effect of daptomycin is a reduction in the bacterial exponential growth rate constant from the baseline in the absence of antibiotic to a lower (positive) growth or (negative) death rate constant observed in the presence of antibiotic. These data confirm that daptomycin exhibits concentration-dependent killing over a wide range of free daptomycin concentrations relative to the MIC and suggest that this is a saturable process similar to the Michaelis-Menten pharmacokinetic elimination of certain drugs.
引用
收藏
页码:2334 / 2337
页数:4
相关论文
共 17 条
[1]  
BRIER GL, 1989, 29TH INT C ANT AG CH
[2]   INVITRO ACTIVITY OF LY146032 (DAPTOMYCIN), A NEW PEPTOLIDE [J].
EHLERT, F ;
NEU, HC .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (01) :84-90
[3]   INVITRO AND INVIVO ACTIVITY OF LY 146032, A NEW CYCLIC LIPOPEPTIDE ANTIBIOTIC [J].
ELIOPOULOS, GM ;
WILLEY, S ;
REISZNER, E ;
SPITZER, PG ;
CAPUTO, G ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (04) :532-535
[4]  
ERDMAN S, 1991, 31ST INT C ANT AG CH
[5]   INVITRO ACTIVITY OF LY146032 AGAINST STAPHYLOCOCCI, STREPTOCOCCI, AND ENTEROCOCCI [J].
FASS, RJ ;
HELSEL, VL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (05) :781-784
[6]   EARLY STAGES OF INVITRO KILLING CURVE OF LY146032 AND VANCOMYCIN FOR STAPHYLOCOCCUS-AUREUS [J].
FLANDROIS, JP ;
FARDEL, G ;
CARRET, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (04) :454-457
[7]   ASSESSMENT OF EFFECTS OF PROTEIN-BINDING ON DAPTOMYCIN AND VANCOMYCIN KILLING OF STAPHYLOCOCCUS-AUREUS BY USING AN INVITRO PHARMACODYNAMIC MODEL [J].
GARRISON, MW ;
VANCEBRYAN, K ;
LARSON, TA ;
TOSCANO, JP ;
ROTSCHAFER, JC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (10) :1925-1931
[8]  
HUOVINEN P, 1987, ANTIMICROB AGENTS CH, V31, P451
[9]   ANTIMICROBIAL ACTIVITY AND SPECTRUM OF LY146032, A LIPOPEPTIDE ANTIBIOTIC, INCLUDING SUSCEPTIBILITY TESTING RECOMMENDATIONS [J].
JONES, RN ;
BARRY, AL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :625-629
[10]   INVITRO ACTIVITY OF LY146032 (DAPTOMYCIN) AGAINST SELECTED AEROBIC-BACTERIA [J].
JORGENSEN, JH ;
MAHER, LA ;
REDDING, JS .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1987, 6 (01) :91-96